Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT-18 in Chinese Patients With Systemic Lupus Erythematosus-Reference-Cited by-同舟云学术

Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT-18 in Chinese Patients With Systemic Lupus Erythematosus

Published:2016-02-22 Issue:8 Volume:56 Page:948-959
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Zhao Qian¹,Chen Xia¹,Hou Yong²,Jiang Ji¹,Zhong Wen¹,Yao Xuejing³,Wang Wenxiang⁴,Li Lin⁴,Fang Jianmin³,Zhang Fengchun²,Hu Pei¹

Affiliation:

1. Clinical Pharmacology Research Center & Translational Medicine Center, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences and Peking Union Medical College; Beijing China

2. Department of Rheumatology; Peking Union Medical College Hospital; Beijing China

3. School of Life Science and Technology; Tongji University; Shanghai China

4. RC Biotechnologies Ltd; Economic and Technological Development Zone; Yantai China

Funder

National Program on Key Research Project of New Drug Innovation

the National High Technology Research and Development Program

National Major Drug Innovation and Development Program

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.686/fullpdf

Reference23 articles.

1. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus;Nestorov;J Pharm Sci,2010

2. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus;Furie;Arthritis Res Ther,2008

3. The efficacy of novel B cell biologics as the future of SLE treatment: a review;Kamal;Autoimmun Rev,2014

4. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator;Moore PA;Science,1999

5. B cell receptor signaling in human systemic lupus erythematosus;Pugh-Bernard;Curr Opin Rheumatol,2006

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases;Journal of Autoimmunity;2024-09

2. Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement;Clinical Rheumatology;2024-05-20

3. A multicenter, randomized, open‐label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis;European Journal of Neurology;2024-05-10

4. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial;Annals of the Rheumatic Diseases;2023-12-21

5. Role of telitacicept in the treatment of IgA nephropathy;European Journal of Medical Research;2023-09-22